nav-left cat-right
cat-right

RICT 2015 Drug Discovery and Selection – Jul...

The French Medicinal Chemistry Society (Société de Chimie Thérapeutique – SCT) is pleased to invite you to Avignon on July 1-3, 2015, for the 51st edition of the International Conference on Medicinal Chemistry (RICT 2015). The scientific programme, which will include over 25 plenary lectures by internationally well-known scientists, will focus on “Drug Discovery and Selection – Understanding Targets and...

Biophysics in Drug Discovery 2015 June 9-12, 2015 ...

The use of biophysical techniques in drug discovery is rapidly increasing, and many pharmaceutical companies have set up in-house biophysical platforms to speed up the target-to-candidate process and improve the quality of small-molecule therapeutics through a better understanding of their interactions with their targets. However, biophysics for drug discovery had not yet been the subject of a dedicated conference: most of...

Bioheterocycles 2015 on June 7-11, 2015 Metz, Fran...

The XVI conference of this series will gather chemists from over the world, involved in the chemistry of heterocycles. The heterocycles in this case will generally be submitted to biological tests as well in medicine as in agriculture. The scientific programme will include plenary and invited lectures by top chemists in the field and will be completed by oral communications and poster presentations. The conference is intended...

5th Cancer Targets & Therapeutics Conference ...

With the rapid progression of molecular biology and genetics, and the subsequent emergence of many new targets, emerging targets and therapeutics provide new opportunities for the prevention and treatment of several major disease systems. The 5th Cancer Targets & Therapeutics Conference, taking place on July 7-8, 2014 in Boston, MA will continue to be a premier event for translational researchers, preclinical scientists...

Potential drug targets for early onset glaucoma

Using a novel high-throughput screening process, scientists have for the first time identified molecules with the potential to block the accumulation of a toxic eye protein that can lead to early onset of glaucoma. Glaucoma is a group of diseases that can damage the eye’s optic nerve and cause vision loss and blindness. Elevated eye pressure is the main risk factor for optic nerve damage. Researchers have implicated a...

Cancer Research UK will repurpose an AstraZeneca a...

Cancer Research UK has struck a deal with AstraZeneca ($AZN) to repurpose an experimental therapy originally developed by the drug giant for asthma and study its ability to fight kidney cancer. Under the agreement, the nonprofit’s drug development office will carry out preclinical testing and early clinical trials of the compound, AZD2098. Cancer Research UK plans to begin enrolling up to 40 patients in an early phase...
Page 5 of 19« First...34567...10...Last »